All In Biotech

Drug Trial Radar · NCT02673931

GLP-1 and Hyperoxia for Organ Protection in Heart Surgery

Efficacy of a Glucagon-like-peptide-1 Agonist and Restrictive vs. Liberal Oxygen Supply in Patients Undergoing Coronary Artery Bypass Grafting or Aortic Valve Replacement - a 2-by-2 Factorial Designed, Randomized Clinical Study

Last checked: Nov 20, 2026Latest source record: Aug 28, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 1,400 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

1,400

Actual

Start

Feb 2016

Primary completion

Sep 2024

Study completion Sep 2024

Sponsor

Lead sponsor
Copenhagen University Hospital, RigshospitaletAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Feb 4, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Factorial
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Patients undergoing open heart surgery are at risk of suffering damage to the heart, brain and kidneys. This study is designed as a 2-by-2 randomized clinical trial with the purpose of investigating the organ protective effects of the glucagon-like-peptide-1 (GLP-1) agonist Exenatide versus placebo and restrictive versus liberal oxygenation during weaning from cardio-pulmonary bypass.

Conditions

  • Coronary Disease
  • Shock, Cardiogenic
  • Renal Failure
  • Stroke
  • Brain Injury
  • Aortic Valve Disease

Interventions

  • Byetta (Lilly, Exenatide)Drug

    See description of arms

  • Conoxia (AGA, oxygen)Drug

    See description arms

  • 20% Human AlbuminDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time in days to the first occurring of the following co-primary end-points throughout the follow-up periodTime frame: Minimum 12 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Rigshospitalet - Copenhagen University Hospital

    Copenhagen, Denmark

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.